Financial Data and Key Metrics Changes - The company reported a net cash used in operating activities of $4.5 million for the quarter, with $3.6 million related to recurring baseline expenditures primarily for R&D and G&A aligned with milestones [33][34] - The company completed an $11.5 million common stock public offering to strategically fund operations while managing dilution [38] Business Line Data and Key Metrics Changes - The HeartBeam system is designed to synthesize a 12-lead ECG and has received foundational FDA clearance for arrhythmia assessment, with a second FDA application for software currently under review [6][7][9] - The VALID ECG study met its clinical endpoints, demonstrating that synthesized ECGs closely approximate standard 12-lead ECGs for arrhythmia assessment [20][40] Market Data and Key Metrics Changes - The target market segment for the HeartBeam system is estimated to be a $500 million serviceable market in the US, with strong demand from patients and physicians [27] - The coronary artery disease market is larger than the atrial fibrillation market, with 20 million patients in the US at elevated risk for heart attacks [28] Company Strategy and Development Direction - The company aims to achieve FDA clearance for the 12-lead synthesis software and prepare for commercialization by the end of the year [41][42] - A strategic collaboration with AccuCardia has been established to enhance the HeartBeam system's capabilities, particularly in automated rhythm assessment [21][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing productive discussions with the FDA, anticipating clearance for the 12-lead synthesis software by the end of the year [62] - The company is focused on building out infrastructure for commercial readiness, including customer support and logistics [25][31] Other Important Information - The company has issued a total of 20 patents worldwide, emphasizing the importance of intellectual property in its strategy [11][26] - The early access program is providing valuable feedback on the HeartBeam system's usability and features [25][46] Q&A Session Summary Question: Insights from the early access program - The company learned valuable insights from real patient interactions, including onboarding and training, which have helped refine the commercial opportunity [45][46] Question: Pricing strategy for commercialization - The anticipated pricing is expected to be between $50 to $100 per month, with potential tiered options for additional services [47][48] Question: Timing for infrastructure build-out - The company plans to start commercialization in Q4 of 2025, following FDA clearance, with initial efforts focused on two target markets [52][55] Question: FDA approval process updates - There have been no disruptions or delays in the FDA approval process, and discussions remain productive [60][62] Question: Competitive position with AccuCardia partnership - The partnership enhances the competitive offering by providing automated assessments for routine recordings, filling a critical gap in the product pipeline [64][66] Question: Manufacturing capabilities and tariff exposure - The company has secured a US-based contract manufacturer to mitigate tariff impacts and ensure quality in early manufacturing runs [72][74]

Company Overview and Strategy - MDB Capital aims to transform deep technology "Big Ideas" into valuable public companies[6] - The company's goal is to enable investors to create a portfolio of 10–12 MDB curated venture-stage companies over time[7] - MDB's platform helps stand up and launch deep tech new category leaders[10] Pipeline and Due Diligence - In 2024, MDB screened 8,964 private and public companies and further examined 219 to identify deep tech ideas[21] - The number of private companies reviewed increased by 107% from 3,391 in 2023 to 7,025 in 2024[22] - The number of public companies under surveillance increased by 35% from 1,432 in 2023 to 1,939 in 2024[22] - Companies further examined increased by 366% from 47 in 2023 to 219 in 2024[22] Financial Performance and Investments - MDB's direct assets increased significantly by 2,092% from $2,016,959 in 2023 to $44,215,968 in 2024[22] - The company completed an IPO for Invizyne Technologies (now eXoZymes Inc (EXOZ)) in November 2024, raising $15 million[21,40] - MDB's initial investment of $5.9 million in eXoZymes translated into a $150 million market cap company[40] - MDB owns 47% of eXoZymes' outstanding stock[40] Market Positioning and Future Outlook - MDB is well-positioned for 2025 due to a significant increase in micro-cap deal opportunities and a growing demand for micro-cap financing[29,34] - Venture Capital fundraising declined by nearly 58% in 2023 and by 23-25% in 2024[31]